Key Highlights
- Johnson & Johnson has won FDA approval for its Dual Energy Thermocool Smarttouch SF Platform, a catheter that toggles between radiofrequency and pulsed field energy to treat atrial fibrillation, with U.S. physicians expected to perform first procedures this summer under a phased rollout.
- The device builds on J&J’s existing single-energy Thermocool catheter and integrates with its Carto mapping system, positioning the company to leverage its electrophysiology strength after losing early market share to rivals in pulsed field ablation.
- Early European experience with the dual-energy version, cleared there since January 2025, suggests it is already used in an estimated 20% to 30% of cases, with J&J executives framing its versatility as a key advantage for complex ablation procedures near sensitive anatomy.
A Strategic Answer to Lost PFA Ground
Johnson & Johnson enters the U.S. dual-energy ablation market after Boston Scientific and Medtronic beat it to launch with pulsed field ablation technology, and after J&J briefly paused U.S. cases of its own single-energy PFA device to investigate reported neurovascular events. The new FDA approval gives the company a second energy option built on its most widely used radiofrequency catheter platform, one that physicians are already broadly trained on, as it works to rebuild share in a fast-moving segment of cardiac ablation.
Versatility as the Core Value Proposition
Company leadership has emphasized that the ability to switch between radiofrequency and pulsed field energy within a single catheter gives physicians added flexibility depending on how complex a given patient’s anatomy is. Ablations performed near structures such as the coronary arteries present particular challenges, and J&J executives argue that access to both energy modalities in one device better equips physicians to navigate those harder cases.
European Experience Offers an Early Read
The dual-energy catheter has already been available in Europe since receiving a CE mark in early 2025, giving J&J a head start in real-world adoption data ahead of its U.S. launch. Company leadership has pointed to strong physician feedback abroad, while outside analysts tracking adoption patterns have estimated the device is being used in roughly a fifth to a third of relevant cases, an early signal of interest as the technology heads into the U.S. market.
Part of a Broader Product Cadence
The approval fits into a stated commitment from J&J’s CEO to bring a new ablation catheter to market every year through the end of the decade, reflecting the company’s intent to compete aggressively in electrophysiology despite trailing PFA rivals to market. With a phased U.S. commercial rollout now underway, J&J is positioning the dual-energy platform as a central piece of its strategy to regain share in the complex end of the ablation procedure spectrum.
By
